Biocon is Asia’s premier biopharmaceutical company is driven by the vision to make a difference to global healthcare through improved access to high quality, life saving biotherapeutics by making them affordable for patience across the world. Company have evolved from manufacturing pharmaceuticals like statins and immunosuppresants, to discovering, developing and producing biologics in chronic therapies such as diabetes, oncology and immunology for global markets. This has translated into a diversified and differentiated pipeline of fermentation derived complex generics, biosimilars that include insulins and monoclonal antibodies and novel biologics. Biocon was among the early movers in industry to pursue a high risk strategy of developing biosimilars for global market.